This is mainly attributed to, and complicated by the heterogeneity of sALS in terms of both clinical and molecular presentation. There are currently very few treatment options available for ALS, with most providing only transitory symptomatic relief. The sporadic form (sALS) occurs in approximately 90% of all ALS cases and cannot be explained by familial inheritance of a specific mutation. Death usually occurs 3 to 5 years post diagnosis. IntroductionĪmyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease that causes the death of motor neurons leading to muscle wastage and eventual paralysis. Stem cells pluripotent stem cells transcriptome umbilical cord-derived stem cells multipotent stem cells (MSC) proteome micro-RNA (miRNA) 1. These analyses may serve as a future guide to both scientists and clinicians alike in defining the utility of such cells in ALS treatment. Although new CSF proteins (FGA, B2M, FN1 and IGFBP3) were observed, but more work is needed to fully elucidate the effect based on larger cohorts in a clinical trial setting. This is the first snapshot of pre-and post-stem cell transplantation in an ALS patient through transcriptomic, epigenomic, and proteomic follow-up elucidating the effect of stem cells in ALS. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited. Molecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS. Recommended citation: Brennan S, Keon M, Su Z, Liu B, Song XM, Zaw T, McKay M, Pascovici D, Saksena NK. Received: Aug| Accepted: Ma| Published: March 29, 2021 Special Issue: Research on Neurodegenerative Diseases ‡ Current Affiliation: G42 Healthcare, Abu Dhabi UAE. Australia Īustralian Proteomic Facility (APAF), Department of Molecular Science, Level 4, Room 432, 4 Wally's Walk, Macquarie University, NSW 2109, Sydney, Australia Neurodegenerative Disease section, Iggy Get Out (IGO), Boundary street, Darlinghurst NSW 2010. Samuel Brennan 1, Matthew Keon 1, Zheng Su 1, Bing Liu 1, Xiao Min Song 2, Thiri Zaw 2, Matthew McKay 2, Donna Pascovici 2, Nitin K. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible. The journal publishes research articles, reviews, communications and technical notes. Papers must be clear and concise, but detailed data is strongly encouraged. Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21 st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm. Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases. OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases.
0 Comments
Leave a Reply. |